934965-51-2
Chemical Structure
CPP44
- CAS. Nr.: 934965-51-2
- Formula:C91H142N28O20S2
- Molecular Weight:2012.41
InChIKey: WJFNDAQUGNLISD-XIVUNSLJSA-N
SMILES: O=C(N[C@@H](CCCNC(N)=N)C(N1[C@@H](CCC1)C(N[C@@H]([C@H](O)C)C(N[C@@H](CCSC)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC2=CC=CC=C2)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC3=CC=C(C=C3)O)C(N[C@@H]([C@H](O)C)C(N[C@@H](CC4=CNC5=CC=CC=C45)C(N[C@@H](CC(N)=O)C(N6[C@@H](CCC6)C(N[C@@H](CCSC)C(N[C@@H](CCCCN)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CCCCN)N
Biological Activity: CPP44 is a tumor lineage-homing cell-penetrating peptide (CPP) that selectively enters myeloid leukemia cells and liver tumor cells. The cellular internalization of CPP44 is associated with M160 (CD163L1), and it mainly enters cells via an ATP- and dynein-dependent, clathrin-independent endocytic pathway. CPP44 can be used in studies related to acute myeloid leukemia, hepatocellular carcinoma, tumor-targeted delivery, and tumor imaging[1][2][3][4].
| Art. -Nr. | Produktname | Reinheit | Beschreibung | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
CPP44 | CPP44 is a tumor lineage-homing cell-penetrating peptide (CPP) that selectively enters myeloid leukemia cells and liver tumor cells. The cellular internalization of CPP44 is associated with M160 (CD163L1), and it mainly enters cells via an ATP- and dynein-dependent, clathrin-independent endocytic pathway. CPP44 can be used in studies related to acute myeloid leukemia, hepatocellular carcinoma, tumor-targeted delivery, and tumor imaging. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Kondo E, et al. Tumour lineage-homing cell-penetrating peptides as anticancer molecular delivery systems. Nature communications. 2012 Jul 17;3:951.
- [2]. Chai M, et al. Carrier-free self-assembled nanomedicine for combination-therapy of acute myeloid leukemia. BMEMat. 2026;e70072.
- [3]. Cai M, et al. Aperture Modulation of Isoreticular Metal Organic Frameworks for Targeted Antitumor Drug Delivery. ACS applied materials & interfaces. 2022 Aug 17;14(32):36366-36378.
- [4]. Essola JM, et al. Tumor suppressor protein-inspired peptide for siRNA delivery and synergistic cancer therapy. Fundamental research. 2025 Sep;5(5):1920-1929.
Keywords
